Results 61 to 70 of about 236,558 (261)

Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. [PDF]

, 2015
The objective of this study is to assess whether pregnancy is associated with an increased risk of liver enzyme elevation (LEE) and severe LEE in HIV-positive women on antiretroviral therapy (ART)
the UK Collaborative HIV Cohort (UK CHIC) Study, the UK, Ireland National Study of HIV in Pregnancy, Childhood (NSHPC),, Sabin, C, Thorne, C, Pillay, D, Huntington, S, Tookey, PA, Newell, ML, Taylor, GP, Anderson, J, Hill, T   +9 more
core  

T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating Antiretroviral Therapy. [PDF]

, 2015
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedTo estimate the ...
Chisenga, Molly, Suzanne Filteau, Andrew J Prendergast, Joshua Siame (756094), Filteau, S, Prendergast, AJ, Paul Kelly, Siame Joshua, Siame, J, Paul Kelly (95510), Prendergast, Andrew J, Chisenga Caroline C., Filteau Suzanne, Filteau, Suzanne, Siame, Joshua, Molly Chisenga, Suzanne Filteau (132124), Prendergast Andrew J., Chisenga, Caroline C, Chisenga, M, Chisenga Molly, Caroline C. Chisenga (634491), Kelly Paul, Chisenga, CC, Molly Chisenga (756095), Caroline C Chisenga, Andrew J. Prendergast (314511), Joshua Siame, Kelly, Paul, Kelly, P   +29 more
core   +2 more sources

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Noma and Noma-like disease in HIV/AIDS patients, a comorbid interaction: A systematic review

Journal of Infection in Developing Countries, 2018
Introduction: Noma is an opportunistic polymicrobial infection that cause necrosis of the mouth and face, with high morbidity and mortality, predominantly affecting malnourished children and persons with debilitating diseases. Cases of noma-like disease
Héctor M Prado-Calleros, Bertha B Castillo-Ventura, Irma Jiménez-Escobar, Juan P Ramírez-Hinojosa, Antonio López-Gómez, Miguel García-de-la-Cruz, Mijal Dayan-Nurko   +6 more
doaj   +1 more source

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy [PDF]

, 2005
Background. Very low rates of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) are achievable with use of highly active antiretroviral therapy (HAART).
Canet, Y, SCHERPBIER H, FORTUNY C, Masuelli, G, Bates, I, A. Ehrnst, BUFFOLANO W, Barlow, P, Caro, MC, SUY A, J. Ma Pena, D. Perez-Tamarit, F. Hawkins, A. Suy, MARTINELLI P, SUAREZ G, Bohlin, AB, EHRNST A, DE MARIA A, Sansone, M, A. De Maria, LIDMAN K, Penn, Z, N. H. Valerius, HAINAUT M, KREYENBROEK M, R. Carreras, R. Tiseo, RABUSIN M, JIMENEZ J, DE JOSE I, Y. Canet, E. G. H. Lyall, Alberico, S, VALERIUS NH, Bernardon, M, Pena, JM, Ferrazi, E, Otero, MC, LOPEZ VILCHEZ MA, E. Ferrazzi, CARRERAS R, I. Bates, Taylor, GP, BOER K, P. Martinelli, M. Rabusin, Mok, J, LEVY J, Bassetti, D, A. Ferrazin, AGANGI A, Ruga, E, de Jose, I, BARLOW P, A. Mur, I. Grosch-Worner, Ferrazin, A, Garcia-Rodriguez, MC, Naver, L, FERRAZI E, ALBERICO S, M. Hainaut, M. Casellas Caro, MOK J, ASENSI BOTET F, Jimenez, J, A. Horban, Fortuny, C, G. P. Taylor, M. Kreyenbroek, GARCIA JG, HAWKINS F, A. De Rossi, COLL O, GOTTA C, Levy, J, Lindgren, S, PAYA A, Ehrnst, A, TAYLOR GP, Asensi-Botet, F, SANSONE M, M. Vinolas, Vinolas, M, Tiseo, R, J. Gonzalez Garcia, M. Bernardon, GOETGHEBUER T, NAVER L, Scherpbier, H, SAVASI V, et al, LOPEZ JRA, F. Asensi-Botet, C. Tibaldi, TIBALDI C, Coll, O, Garcia, JG, Marczynska, M, A. B. Bohlin, I. de Jose, TISEO R, PENN Z, De Rossi, A, Hainaut, M, Gotta, C, PEREZ TAMARIT DP, J. R. Arribas Lopez, RUGA, EZIA MARIA, C. Benedetto, T. Goetghebuer, MUR A, BOHLIN AB, Giaquinto, C, J. Mok, Goetghebuer, T, S. Marini, Carreras, R, OTERO MC, S. Lindgren, CANET Y, K. Boer, A. Viganò, Belfrage, E, GIAQUINTO, CARLO, H. Scherpbier, Valerius, NH, D. Bassetti, Anzen, B, LINDGREN S, Lopez-Vilchez, MA, BASSETTI D, V. Savasi, Kreyenbroek, M, Marini, S, Peltier, A, M. C. Garcia-Rodriguez, C. Ladron de Guevara, W. Buffolano, LYALL EGH, Mur, A, J. Levy, de Guevara, CL, DE ROSSI, ANITA, CARO MC, Z. Penn, ANZEN B, Hawkins, F, GROSCH WORNER I, VINOLAS M, C. Giaquinto, Grosch-Worner, I, Niemiec, T, J. Jimenez, B. Anzen, Suarez, G, Martinelli, P, Paya, A, O. Coll, J. M. Perez, G. Masuelli, Boer, K, Buffolano, W, M. A. Lopez-Vilchez, BELFRAGE E, Rovira, Perez-Tamarit, DP, Lidman, K, C. Gotta, E. Ruga, VIGANO A, M. Sansone, E. Belfrage, Tibaldi, C, DE GUEVARA CL, S. Alberico, BATES I, Perez, JM, A. Peltier, P. Barlow, A. Paya, PELTIER A, G. Suarez, FERRAZIN A, Lopez, JRA, Vigano, A, Agangi, A, PENA JM, K. Lidman, Horban, A, C. Fortuny, M. C. Otero, A. Agangi, De Maria, A, BERNARDON M, GARCIA RODRIGUEZ MC, T. Niemiec ̧ M. Marczynskam, Benedetto, C, Rabusin, M, Suy, A, Lyall, EGH, PEREZ JM, L. Naver, Savasi, V   +204 more
core   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

Arthritis Care &Research, EarlyView.
Catherine Deffendall, Jodi Backalar, Elizabeth Acevedo Zapata, Adriana Della Porta, Lorin Bibb, Tyler Reese, Charlotte M. Brown   +6 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso

Journal of the International AIDS Society, 2014
Introduction Gender differences in antiretroviral therapy (ART) outcomes are critical in sub‐Saharan Africa. We assessed the association between gender and virologic failure among adult patients treated in a public routine clinic (one of the largest in ...
Pauline Penot, Arsène Héma, Guillaume Bado, Firmin Kaboré, Ibrahim Soré, Diamasso Sombié, Jean‐Richard Traoré, Jean‐Baptiste Guiard‐Schmid, Arnaud Fontanet, Laurence Slama, Adrien Bruno Sawadogo, Christian Laurent   +11 more
doaj   +1 more source

Larger Subcortical Gray Matter Structures and Smaller Corpora Callosa at Age 5 Years in HIV Infected Children on Early ART

Frontiers in Neuroanatomy, 2017
Sub-Saharan Africa is home to 90% of HIV infected (HIV+) children. Since the advent of antiretroviral therapy (ART), HIV/AIDS has transitioned to a chronic condition where central nervous system (CNS) damage may be ongoing.
Steven R. Randall, Christopher M. R. Warton, Martha J. Holmes, Mark F. Cotton, Barbara Laughton, Andre J. W. van der Kouwe, Ernesta M. Meintjes   +6 more
doaj   +1 more source

The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study [PDF]

, 2005
Background. Relatively few data are available on the association between the use of specific antiretroviral drugs and the rate of viral rebound in those attaining a viral load (VL) 500 copies/ mL).
Smith, CJ, Smith, C J, Phillips, AN, Porter, K, Scullard, G, Hill, T, Fisher, M, Phillips, A N, Easterbrook, P, Johnson, MA, Gilson, R, Sabin, C A, Gazzard, B, United Kingdom HIV Cohort Study, Matthias, R, Sabin, CA, Johnson, M A   +16 more
core   +1 more source